Emerging patterns suggest Moderna's two-dose vaccine might have a slight edge over Pfizer's in the long run.

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were both leaders in the coronavirus vaccine market. However, as sales of these products have declined significantly in recent years -- due to the ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The year-to-date scoreboard tells the same story. Moderna ...

The two New Jersey suits assert eight patents against Pfizer and 10 against Moderna, extending existing mRNA litigation beyond delivery technology to manufacturing, purity and non-COVID respiratory ...

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. Today's catalyst is ...